HUE050878T2 - Combination of anti-cd20 antibody and pi3 kinase selective inhibitor - Google Patents

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Info

Publication number
HUE050878T2
HUE050878T2 HUE16185090A HUE16185090A HUE050878T2 HU E050878 T2 HUE050878 T2 HU E050878T2 HU E16185090 A HUE16185090 A HU E16185090A HU E16185090 A HUE16185090 A HU E16185090A HU E050878 T2 HUE050878 T2 HU E050878T2
Authority
HU
Hungary
Prior art keywords
antibody
combination
selective inhibitor
kinase selective
kinase
Prior art date
Application number
HUE16185090A
Other languages
Hungarian (hu)
Inventor
Michael Weiss
Hari Miskin
Peter Sportelli
Swaroop K V S Vakkalanka
Original Assignee
Tg Therapeutics Inc
Rhizen Pharmaceuticals S A
Laboratoire Francais Du Fractionnement Et Des
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tg Therapeutics Inc, Rhizen Pharmaceuticals S A, Laboratoire Francais Du Fractionnement Et Des filed Critical Tg Therapeutics Inc
Publication of HUE050878T2 publication Critical patent/HUE050878T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HUE16185090A 2012-11-02 2013-11-01 Combination of anti-cd20 antibody and pi3 kinase selective inhibitor HUE050878T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4595CH2012 2012-11-02
US201361771812P 2013-03-02 2013-03-02

Publications (1)

Publication Number Publication Date
HUE050878T2 true HUE050878T2 (en) 2021-01-28

Family

ID=73052261

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16185090A HUE050878T2 (en) 2012-11-02 2013-11-01 Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Country Status (4)

Country Link
ES (1) ES2813343T3 (en)
HR (1) HRP20201196T1 (en)
HU (1) HUE050878T2 (en)
PT (1) PT3150256T (en)

Also Published As

Publication number Publication date
PT3150256T (en) 2020-08-31
ES2813343T3 (en) 2021-03-23
HRP20201196T1 (en) 2020-11-13

Similar Documents

Publication Publication Date Title
IL238564B (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
HRP20180953T1 (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
IL267681A (en) Selective grp94 inhibitors and uses thereof
HK1223089A1 (en) Kinase inhibitor and use thereof
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
HK1219421A1 (en) Combination of kinase inhibitors and uses thereof
EP2683243A4 (en) Pi3 kinase inhibitors and uses thereof
EP2721031A4 (en) Bromodomain inhibitors and uses thereof
EP2705039A4 (en) Bromodomain inhibitors and uses thereof
HK1217949A1 (en) Dual selective pi3 delta and gamma kinase inhibitors pi3
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
EP2833889A4 (en) Protein kinase c inhibitors and uses thereof
EP3076963A4 (en) Combination of aurora kinase inhibitors and anti-cd30 antibodies
PT3150256T (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
EP2986627A4 (en) INHIBITORS OF THE Eph-A RECEPTOR AND USES THEREOF